Lybalvi Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Lybalvi (Olanzapine/Samidorphan) is a central nervous system drug consisting of two components: olanzapine and samidorphan. Olanzapine is an approved second-generation antipsychotic that improves the positive and negative symptoms of schizophrenia by acting on dopamine and serotonin receptors. However, long-term use of olanzapine may cause weight gain as well as metabolic problems such as increased triglyceride and cholesterol levels. Samidorphan is an opioid that acts as an antagonist by binding to the μ-opioid receptor and as a partial agonist at the kappa- and delta-opioid receptors. Samidorphan was originally developed to treat alcohol use disorder and binge eating disorder, but was later found to reduce the risk of weight gain when used in combination with olanzapine. This property of samidorphan makes it part of the Lybalvi combination drug, which helps manage symptoms in patients with schizophrenia and bipolar I disorder while reducing the weight gain problem caused by olanzapine.
Lybalvi Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
